

Genomic footprints of activated telomere maintenance mechanisms in cancer

Lina Sieverling, Chen Hong, Sandra D. Koser, Philip Ginsbach, Kortine Kleinheinz, Barbara Hutter, Delia M. Braun, Isidro Cortés-Ciriano, Ruibin Xi, Rolf Kabbe, Peter J. Park, Roland Eils, Matthias Schlesner, Benedikt Brors, Karsten Rippe, David T. W. Jones, Lars Feuerbach

Angaben zur Veröffentlichung / Publication details:










Sieverling, Lina, Chen Hong, Sandra D. Koser, Philip Ginsbach, Kortine Kleinheinz, Barbara Hutter, Delia M. Braun, et al. 2020. "Genomic footprints of activated telomere maintenance mechanisms in cancer." *Nature Communications* 11 (1): 733.
<https://doi.org/10.1038/s41467-019-13824-9>.

ARTICLE

<https://doi.org/10.1038/s41467-019-13824-9>

OPEN

Genomic footprints of activated telomere maintenance mechanisms in cancer

Lina Sieverling ^{1,2}, Chen Hong ^{1,2}, Sandra D. Koser^{1,2}, Philip Ginsbach³, Kortine Kleinheinz^{3,4}, Barbara Hutter ¹, Delia M. Braun ^{2,5}, Isidro Cortés-Ciriano ^{6,7,8}, Ruibin Xi ⁹, Rolf Kabbe³, Peter J. Park ^{6,8}, Roland Eils^{3,4}, Matthias Schlesner ¹⁰, PCAWG-Structural Variation Working Group, Benedikt Brors^{1,11}, Karsten Rippe ⁵, David T.W. Jones^{11,12,13}, Lars Feuerbach^{1*} & PCAWG Consortium

Cancers require telomere maintenance mechanisms for unlimited replicative potential. They achieve this through TERT activation or alternative telomere lengthening associated with ATRX or DAXX loss. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, we dissect whole-genome sequencing data of over 2500 matched tumor-control samples from 36 different tumor types aggregated within the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium to characterize the genomic footprints of these mechanisms. While the telomere content of tumors with ATRX or DAXX mutations (ATRX/DAXX^{trunc}) is increased, tumors with TERT modifications show a moderate decrease of telomere content. One quarter of all tumor samples contain somatic integrations of telomeric sequences into non-telomeric DNA. This fraction is increased to 80% prevalence in ATRX/DAXX^{trunc} tumors, which carry an aberrant telomere variant repeat (TVR) distribution as another genomic marker. The latter feature includes enrichment or depletion of the previously undescribed singleton TVRs TTCGGG and TTTGGG, respectively. Our systematic analysis provides new insight into the recurrent genomic alterations associated with telomere maintenance mechanisms in cancer.

¹Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. ²Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany. ³Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. ⁴Department for Bioinformatics and Functional Genomics, Institute for Pharmacy and Molecular Biotechnology (IPMB) and BioQuant, 69120 Heidelberg, Germany. ⁵Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, 69120 Heidelberg, Germany. ⁶Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts 02115, USA. ⁷Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK. ⁸Ludwig Center at Harvard, Boston, Massachusetts 02115, USA. ⁹School of Mathematical Sciences and Center for Statistical Science, Peking University, Beijing 100871, China. ¹⁰Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. ¹¹German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. ¹²Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. ¹³Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg, Germany. PCAWG-Structural Variation Working Group authors and their affiliations appear at the end of the paper. PCAWG Consortium members and their affiliations appear in the Supplementary Information. *email: l.feuerbach@dkfz-heidelberg.de

Telomeres are nucleoprotein complexes at the ends of chromosomes that prevent DNA degradation and genome instability¹. The typically 10–15 kb long chromosome termini are composed of long stretches of TTAGGG (t-type) repeat arrays with an increasing number of variants toward proximal, subtelomeric regions, the most common being TGAGGG (g-type), TCAGGG (c-type), and TTGGGG (j-type) repeats^{2,3}.

Telomeres play an important role in cellular aging, as they are shortened with each cell division and finally trigger a DNA damage response resulting in senescence^{4,5}. To avoid this permanent growth arrest, cells with unlimited proliferative potential need to extend their telomeres. In humans, telomeric DNA is synthesized by telomerase, an enzyme that is composed of the reverse transcriptase TERT and the RNA template TERC. This complex is active in the germline and stem cells, but absent in most somatic cells⁶. Telomerase is upregulated in ~85% of human cancers by different genetic aberrations, including *TERT* amplifications⁷, rearrangements⁸, or mutations in the *TERT* promoter^{9,10}. The remaining tumors employ an alternative lengthening of telomeres (ALT) pathway, which is based on DNA recombination of telomeric sequences¹¹. Details on the ALT mechanism remain elusive, but it has been associated with loss-of-function mutations in the chromatin remodeling genes *ATRX* (α -thalassaemia/mental retardation syndrome X-linked) and *DAXX* (death domain-associated protein)¹². Telomeres of ALT cells characteristically have heterogeneous lengths and contain a range of telomere variant repeats (TVRs)^{13–15}. Other hallmarks of ALT include ALT-associated promyelocytic leukemia nuclear bodies, abundance of extra-chromosomal telomeric repeats of various forms (such as C-circles), and genome instability^{11,16}.

While normally located at the chromosome termini, telomere sequences are also found within chromosomes. As such, interstitial telomeric sequences with large blocks of telomere repeats exist in humans and other species, which probably arose from ancestral genome rearrangements or other evolutionary events¹⁷. Recently, also ALT-specific, targeted telomere insertions into chromosomes have been described that lead to genomic instability¹⁸. Another source for unexpected telomere repeat occurrence is the stabilizing function of telomeres at broken chromosomes. After a double-strand break, telomeres can be added de novo to the unprotected break sites (“telomere healing”) ^{19,20} or acquired from other chromosomal positions (“telomere capture”) ^{21,22}.

The here presented study was conducted within the scope of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole-genome sequencing (WGS) data from 2658 cancers across 38 tumor types generated by the ICGC and TCGA projects. This data was reanalyzed with standardized, high-accuracy pipelines to align to the human genome (reference build hs37d5), and identify germline variants and somatically acquired mutations, as described in ref. ²³.

Here, we characterize the telomere landscape of 2519 tumor samples from 36 different tumor types using the WGS alignments, somatic mutation, and chromothripsis calls provided by the PCAWG Consortium^{23,24}. Besides determining telomere content and searching for mutations associated with different telomere maintenance mechanisms (TMMs), we systematically detect 2683 somatic telomere insertions and show that different TMMs are associated with the enrichment of previously undescribed singleton TVRs.

Results

Telomere content across cohorts. Due to the repetitive nature of telomere sequences, short sequencing reads from telomeres cannot be uniquely aligned to individual chromosomes. However, a

mean telomere content for the tumor as a whole can be estimated from the number of reads containing telomere sequences²⁵. Here, we extracted reads containing at least six telomere repeats per 100 bases, allowing the canonical telomere repeat TTAGGG and the three most common TVRs TCAGGG, TGAGGG, and TTGGGG. The telomere content was defined as the number of unaligned telomere reads normalized by sequencing coverage and GC content. Of the 2583 high-quality tumor samples available in PCAWG, we selected those from donors with a single tumor sample. From each donor, a control sample was available. In most cases this consisted of a blood sample, but could also stem from tumor-adjacent or other tissue²³. The telomere content was determined for the remaining 2519 tumor samples and matched controls from 36 different tumor types. Several of these tumor types were not covered in a recent pan-cancer overview of telomere lengths²⁶, including medulloblastoma, pilocytic astrocytoma, chronic lymphocytic leukemia, pancreatic endocrine cancers, benign bone cancer, and osteosarcoma. All relevant donor information and results used in this study are summarized in Supplementary Data 1.

Telomere content of the controls anticorrelated with age ($r = -0.36$, Spearman correlation; Supplementary Fig. 1a). However, this age effect only has a low contribution to the strong correlation between the telomere content of the tumor and control samples ($r = 0.47$ and $r_{\text{partial}} = 0.46$ given the patient age, Spearman correlation, Supplementary Fig. 1b). Thus, the association of tumor and control telomere content must mainly be caused by other genetic^{27,28}, environmental²⁹, or technical factors²⁶. We normalized for these contributions by computing the ratio of tumor and control telomere content per individual.

Most tumor samples had a lower telomere content than the matched control (Fig. 1a). However, there were systematic differences between the different tumor types. Among those with the highest telomere content increase were osteosarcomas and leiomyosarcomas (median telomere content tumor/control log₂ ratios = 0.7 and 0.6, respectively). A particularly low telomere content was found in colorectal adenocarcinoma and medulloblastoma (median telomere content tumor/control log₂ ratios = -1.0).

Prevalence of TMM-associated mutations. Different types of mutations in *ATRX* or *DAXX*, and at the *TERT* locus have been associated with ALT and telomerase activation, respectively. We therefore searched for these types of somatic mutations to infer the active TMM in a given tumor. Somatic mutations in *ATRX*, *DAXX*, or *TERT* were found in 16% of tumor samples. In total, 64 tumor samples had truncating *ATRX* ($n = 53$) or *DAXX* alterations ($n = 11$), and are referred to as *ATRX/DAXX*^{trunc} in the following analysis. Of note, 10 of the 11 *DAXX* alterations were found in pancreatic endocrine tumors, while *ATRX* mutations were seen in a wider variety of entities. An additional 46 samples had nontruncating *ATRX/DAXX* simple nucleotide variants. *TERT* alterations (*TERT*^{mod}) were detected in 270 of the 2519 tumor samples (11%). The latter group comprised 198 activating C228T or C250T promoter mutations (of which 132 were obtained from the PCAWG simple nucleotide variant consensus calls and the remaining were detected with a targeted approach), 11 amplifications leading to at least six additional *TERT* copies, 55 structural variations within 20 kb upstream of *TERT* (*TERT*^{SV}), and 6 samples with more than one of these modifications. Additionally, 18 tumor samples had both *ATRX/DAXX* truncating or other missense mutations and *TERT* alterations.

“Enhancer hijacking” near the *TERT* transcription start site (TSS) has been described in neuroblastoma⁸ and has recently been




Fig. 1 Telomere content is increased in ATRX/DAXX^{trunc} samples. **a** Overview of the telomere content distribution of all analyzed tumor types. The number of samples in each tumor type is indicated. Cohorts with sample sizes <15 are not shown. **b** TMM-associated mutations in different tumor types. **c** Telomere content in samples with different TMM-associated mutations. **d** TERT expression in samples with different TMM-associated mutations. The center lines of the boxplots are the medians, the bounds of the boxes represent the first and third quartiles, the upper and lower whiskers extend from the hinge to the largest or smallest value, respectively, no further than $1.5 \times \text{IQR}$ from the hinge (where IQR is the interquartile range, or distance between the first and third quartiles). **** $p < 0.0001$, Wilcoxon rank-sum tests.

indicated in further cancer types²⁶. In our data set, the strikingly focal distribution of structural variations upstream of the *TERT* TSS also points to this phenomenon (Supplementary Fig. 2). Further evidence is given by the direct overlap of 40% ($n = 25/62$) of the juxtaposed positions within 20 kb upstream of the *TERT* TSS with enhancers from the dbSUPER database³⁰. In contrast, only 13% ($n = 9/69$) of the juxtaposed positions between 20 and 1000 kb corresponded to a predicted super-enhancer. Besides in melanoma (13% prevalence), chromophobe renal cell (9%), hepatocellular (9%), bladder transitional cell (4%), biliary (3%), and renal clear cell carcinoma (3%), previously undescribed *TERT*^{SV} in osteosarcoma (9%) and stomach adenocarcinoma (1%) were found. Moreover, the subtype-specific histological classification available in this study showed that *TERT*^{SV} were more frequent in liposarcoma (32%) than in leiomyosarcoma (7%).

The tumor types with the highest prevalence of *ATRX*/*DAXX*^{trunc} mutations were liposarcomas (32%), adult lower grade gliomas (28%), pancreatic endocrine tumors (23%), and osteosarcoma (17%; Fig. 1b and Supplementary Fig. 3a, b), all of which have previously been associated with ALT^{12,31}. *TERT*^{mod} were most prevalent in transitional cell bladder cancer (70%), glioblastoma (67%), lower grade gliomas (61%), and melanoma (51%).

The telomere content in *TERT*^{mod} samples differed significantly from that in *ATRX*/*DAXX*^{trunc} samples ($p = 1.1 \times 10^{-9}$, Wilcoxon rank-sum test; Fig. 1c, a detailed overview is shown in Supplementary Fig. 4a). On average, telomere content was gained in *ATRX*/*DAXX*^{trunc} (mean telomere content tumor/control log2 ratio = 0.3), while telomere sequences were lost in *TERT*^{mod} samples (mean telomere content tumor/control log2 ratio = -0.4). Samples with nontruncating *ATRX*/*DAXX* simple nucleotide variants had a similar telomere content as *TERT*^{mod} samples ($p > 0.05$, Wilcoxon rank-sum test), suggesting that most of the nontruncating *ATRX*/*DAXX* mutations are passenger events. In *TERT*^{mod} samples and samples with unknown TMM, the telomere content correlated with *TERT* expression ($r = 0.20$, Pearson correlation; $p = 4.1 \times 10^{-10}$, significance of fitted linear regression model) and *TERT* expression was significantly higher in *TERT*^{mod} samples than in *ATRX*/*DAXX*^{trunc} samples ($p = 1.3 \times 10^{-9}$, Wilcoxon rank-sum test; Fig. 1d, detailed overviews are shown in Supplementary Figs. 3c and 4b).

High amount of telomere insertions in *ATRX*/*DAXX*^{trunc} tumors. To find insertions of telomeres into nontelomeric regions of the genome, we searched for tumor-specific discordant paired-end reads, where one end maps to the chromosome and the other end is telomeric. Exact positions of the insertions were determined from reads spanning the junction site and visual inspection (Fig. 2).

Overall, 2683 telomere insertions were detected. These were distributed unevenly between samples and different tumor types (Fig. 3a). Telomere insertions were found in 27% of the tumor samples, with counts ranging between 1 and 228 telomere insertion events. The tumor types with the highest amount of telomere insertions per tumor sample were liposarcoma, leiomyosarcoma, and osteosarcoma, all of which also had a relatively high mean telomere content. In fact, the number of telomere insertions positively correlated with the telomere content ($r = 0.19$, Spearman correlation). Moreover, the number of telomere insertions was associated with the number of genomic breakpoints in the sample ($r = 0.38$, Spearman correlation). To test for a synergistic effect, linear models that predict telomere insertions from telomere content and breakpoint abundance with and without an interaction term were computed. The models with the interaction term ($p = 8.8 \times 10^{-234}$) performed substantially better than purely additive models ($p = 5.8 \times 10^{-90}$).

There was clearly a higher percentage of samples with telomere insertions in *ATRX*/*DAXX*^{trunc} tumors (80%) than *TERT*^{mod} tumors (28%; Fig. 3b). As expected, *ATRX*/*DAXX*^{trunc} samples also had a higher number of breakpoints (mean = 733) than *TERT*^{mod} samples (mean = 291; Fig. 3c). Overall, the fraction of genomic breakpoints overlapping with telomere insertion sites was significantly higher in *ATRX*/*DAXX*^{trunc} than *TERT*^{mod} samples ($p = 1.7 \times 10^{-20}$, Wilcoxon rank-sum test; Fig. 3d). In agreement with the high breakpoint frequency, chromothripsis (numerous chromosomal rearrangements occurring in a single event)³² was more prevalent in the *ATRX*/*DAXX*^{trunc} samples (59%) compared to *TERT*^{mod} samples (34%) and samples without *ATRX*/*DAXX*^{trunc} and *TERT*^{mod} mutations (29%). Similarly, *ATRX*/*DAXX*^{trunc} samples were more likely to have an autosomal breakage-fusion-bridge (BFB) event (44%) than the remaining samples (*TERT*^{mod}: 31%, other: 32%). In *ATRX*/*DAXX*^{trunc} samples, autosomal chromosome arms that showed evidence for BFB cycles and chromothripsis had the highest incidence of telomere insertions (Supplementary Fig. 5).

Correlation analysis of telomere insertions and mutations in telomere maintenance-associated genes from the TelNet database³³ [<http://www.cancertelsys.org/telnet>] revealed significant association with *TP53* ($q = 1.9 \times 10^{-42}$), *ATRX* ($q = 2.6 \times 10^{-6}$), *PLCB2* ($q = 7.8 \times 10^{-4}$), *MEN1* ($q = 0.017$), *TSSC4* ($q = 0.017$), *RBI* ($q = 0.018$), *DAXX* ($q = 0.019$), and *ABCC8* mutations ($q = 0.04$, Wilcoxon rank-sum tests after Benjamini–Hochberg correction). Most of these genes have been implicated in the maintenance of telomere length or structure in humans (Supplementary Table 1). The exceptions are *PLCB2* and *ABCC8*, whose homologues have so far only been reported in association with telomere length regulation in yeast^{34,35}.

The detected telomere insertions were scattered across different chromosomes and regions within the chromosome (Supplementary Fig. 6). No clear preferential insertion sites were identified, but several de novo telomere junctions occurred at the chromosome ends (5% within 50 kb of the first or last chromosomal segment). A total of 44% of the telomere insertions were in genes, and 8% of these disrupted exons. Several tumor suppressor genes were affected, e.g., *CHEK1* encoding for a protein involved in cell cycle arrest upon DNA damage³⁶ (Fig. 2a).

Of note, patterns of microhomology were observed in 79% of telomere insertions with t-type repeats at the junction site (Supplementary Fig. 7).

Frequent copy number losses at telomere insertion sites. Most of the telomere insertions were one-sided (98%), i.e., telomere sequences were only attached to one side of the breakpoint (Fig. 2a). Telomere insertions were defined as two-sided, if there was a second telomere insertion event downstream in the opposite orientation (Fig. 2b). Two-sided telomere insertions can occur via a telomere sequence that bridges two chromosome fragments or, alternatively, telomere sequences are independently fused to both ends of the chromosome break. Reads supporting the first scenario were found in 14 of the 25 two-sided telomere insertions pairings. For the other cases, the inserted repeat sequence was too long to distinguish between the two scenarios.

Because so many breakpoints were one-sided, we investigated the fate of the corresponding broken fragment using complementary information from copy number changes and structural variation annotation (Fig. 3e). As expected, one-sided telomere insertions coincided most frequently with copy number loss of the adjacent segment (46%, Fig. 2c). In contrast, copy number gains of the fragment were rare (6%). Surprisingly, telomere insertions were frequently located at copy-number neutral sites




Fig. 2 Examples of telomere insertions. **a** One-sided telomere insertion in liposarcoma sample SP121774. Blue tracks show the sequencing coverage; light blue represents clipped sequences. Individual reads are grey and clipped bases are colored. Dark grey reads represent the nontelomeric end of a discordant read pair. **b** Two-sided telomere insertion in breast adenocarcinoma sample SP5636. Nontelomeric clipped bases are transparent. **c** One-sided telomere insertion accompanied by copy number loss of the adjacent chromosome end in glioblastoma sample SP29559. Arches represent structural variations. **d** Multiple telomere insertions in a chromosome that underwent chromothripsis in melanoma sample SP124441. **e** One-sided telomere insertion accompanied by a translocation of the adjacent chromosome segment in pancreatic adenocarcinoma sample SP125764.

(42%). Overlaps with regions of chromothripsis were found for 25% and structural variations without chromothripsis overlap (including telomere insertions) were detected near the insertion site for 28% of the copy-number neutral cases (Fig. 2d, e). The remaining telomere insertions at copy-number neutral sites are likely to be subclonal (Supplementary Fig. 8a) or have undetected structural variations nearby (Supplementary Fig. 8b).

Occasional TERRA expression at telomere insertions. ALT-positive tumors have been associated with elevated levels of long noncoding telomeric repeat-containing RNA (TERRA)¹⁶. We searched for TERRA expression in the RNA-sequencing data of 867 tumor samples. In line with the results of Barthel et al.²⁶, TERRA levels were higher in ATRX/DAXX^{trunc} compared to TERT^{mod} samples ($p = 5.0 \times 10^{-7}$, Wilcoxon rank-sum test, Supplementary Fig. 9). In 16 samples, evidence for TERRA expression at telomere insertion sites was found. For most of these, the number of split reads supporting TERRA expression was low (between 1 and 8 reads). However, 146 TERRA reads expressed from only two telomere insertion sites were detected in an ATRX/DAXX^{trunc} liposarcoma sample, making up almost 6% of its total TERRA read count. This percentage is likely to be notably higher, as the short read length does not allow assignment of the total number of TERRA reads stemming from these telomere insertions. Thus, TERRA is not exclusively transcribed from TSSs in the subtelomeric region but can also arise from telomere

insertions. Of note, these telomere insertion transcripts do not always contain the canonical UUAGGG repeat but can also be composed of the reverse complement CCCUAA.

Enrichment of singleton TVRs in ATRX/DAXX^{trunc} samples.

It has previously been shown that ALT leads to an increased integration of TVRs into telomeres, the most common ones being hexamers of the type NNNGGG¹⁵. To detect differences in the telomere composition of ATRX/DAXX^{trunc} and TERT^{mod} tumors, we therefore searched for NNNGGG repeats in telomere reads. The most frequent TVRs across all tumor samples were TGAGGG, TCAGGG, and TTGGGG (Supplementary Fig. 10), which are known to be enriched in proximal telomeric regions^{2,3}.

These and the seven other most frequent TVRs (TAAGGG, GTAGGG, CATGGG, TTCGGG, CTAGGG, TTTGGG, and ATAGGG) were chosen to search for common telomere repeat combinations. For this, the neighboring 18 base pairs on either side of the TVRs were determined (Supplementary Data 2). Most TVRs were surrounded by many different pattern combinations (e.g., TTGGGG). Others were dominated by a certain repeat context, which was similar in ATRX/DAXX^{trunc} and TERT^{mod} tumors (e.g., CATGGG or ATAGGG). However, TTCGGG stood out, as 41% of the TVRs in ATRX/DAXX^{trunc} samples were surrounded by canonical t-type repeats, whereas this context was observed for only 4% of TTCGGG TVRs in TERT^{mod} tumors.




Fig. 3 Insertion of telomere sequences into nontelomeric chromosomal regions. **a** Number of telomere insertions in samples of different tumor types. The tumor types are sorted by mean telomere content tumor/control log2 ratios. Cohorts with sample sizes <15 are not shown. **b** Number of telomere insertions in samples with different TMM-associated mutations. **c** Number of breakpoints in samples with different TMM-associated mutations. **d** Percent of breakpoints coinciding with telomere insertions in samples with different TMM-associated mutations. The center line of the boxplot is the median, the bounds of the box represent the first and third quartiles, the upper and lower whiskers extend from the hinge to the largest or smallest value, respectively, no further than $1.5 \times \text{IQR}$ from the hinge (where IQR is the interquartile range, or distance between the first and third quartiles). **** $p < 0.0001$, Wilcoxon rank-sum test. **e** Copy number changes of adjacent segments accompanying telomere insertions. “Complex” means that the copy numbers between segments differ in more than four copies. Overlaps with regions of chromothripsis are indicated. For telomere insertions that did not overlap with regions of chromothripsis, structural variations, or additional telomere insertions within 10 kb are indicated.




Fig. 4 Singleton TVRs enriched or depleted in ATRX/DAXX^{trunc} samples. **a** Receiver operating characteristic for the classification of samples with ALT-associated mutations from telomere variant repeats. Red: no specific sequence context required. Blue: singletons ((TTAGGG)₃-NNNGGG-(TTAGGG)₃). The more the area under the curve (AUC) deviates from 0.5, the better the repeat occurrence distinguishes ATRX/DAXX^{trunc} from TERT^{mod} samples. **b** Pattern count tumor/control log₂ ratios of all patients plotted against telomere content tumor/control log₂ ratios for selected singletons. The regression line through the TERT^{mod} samples is shown in green and is defined as the expected pattern count in the following. **c** Distance to the expected singleton repeat count in ATRX/DAXX^{trunc} and TERT^{mod} samples. The center line of the boxplot is the median, the bounds of the box represent the first and third quartiles, the upper and lower whiskers extend from the hinge to the largest or smallest value, respectively, no further than 1.5 × IQR from the hinge (where IQR is the interquartile range, or distance between the first and third quartiles). **** $p < 0.0001$; *** $p < 0.001$, Wilcoxon rank-sum tests after Bonferroni correction. The profiles of all analyzed patterns are shown in Supplementary Figs. 11 and 13.

Following up on this observation, we compared variant hexamers surrounded by at least three t-type repeats on either side ("singletons") to TVRs in an arbitrary sequence context. This revealed that singletons are generally well suited to distinguish ATRX/DAXX^{trunc} from TERT^{mod} samples (Fig. 4a, an overview of all patterns is shown in Supplementary Fig. 11). The remaining variant analysis therefore focused on such TVR singletons. CATGGG was excluded as it did not occur as singletons. For the other TVRs, the median of absolute counts varied between 12 and 100, but counts in individual tumor samples reached >10,000 (Supplementary Fig. 12).

As expected, normalized singleton repeat counts generally rose with increasing telomere content (Fig. 4b, an overview of all

patterns is shown in Supplementary Fig. 13). However, TGAGGG, TCAGGG, TTGGGG, and TTCGGG singletons had significantly higher counts than expected in ATRX/DAXX^{trunc} compared to TERT^{mod} samples ($p = 7.3 \times 10^{-11}$, 7.9×10^{-6} , 5.6×10^{-4} , and 5.8×10^{-13} , respectively, Wilcoxon rank-sum test after Bonferroni correction; Fig. 4c). Especially, TGAGGG and TTCGGG seemed to be highly interspersed in a subset of ATRX/DAXX^{trunc} tumors. In contrast, TTTGGG singletons were observed less frequently in ATRX/DAXX^{trunc} tumors ($p = 3.8 \times 10^{-12}$, Wilcoxon rank-sum test after Bonferroni correction).

This seemingly ALT-specific TVR enrichment or depletion occurred in different tumor types, with the highest prevalence in leiomyosarcomas (60%), pancreatic endocrine tumors (42%),

liposarcomas (37%), osteosarcomas (29%), and lower grade gliomas (28%; Supplementary Table 2). In the ATRX/DAXX^{trunc} samples, singleton TVR occurrences correlated with each other (Supplementary Fig. 14). The strongest correlations were between TGAGGG occurrence and TTCGGG and TTGGGG singletons ($r = 0.57$ and $r = 0.58$, respectively, Spearman correlation).

ALT prediction. ALT has several different hallmarks with which it can be reliably identified¹¹. However, most of these are not detectable in short-read WGS data. Using ATRX/DAXX^{trunc} as indicators of ALT, we have shown several possible TMM classification features based on WGS. Most ATRX/DAXX^{trunc} samples are already separated well from TERT^{mod} samples by non-supervised clustering of normalized TGAGGG, TCAGGG, TTGGGG, TTCGGG, and TTTGGG singleton repeat counts (Supplementary Fig. 15). As expected, the clusters of ATRX/DAXX^{trunc} samples had a high telomere content and a high number of telomere insertions relative to the total number of breakpoints. These features were further used to build a random forest classifier distinguishing ATRX/DAXX^{trunc} from TERT^{mod} samples (area under the curve: 0.95; sensitivity: 0.73; specificity: 0.99; all after 10-fold cross-validation). The variables with the highest importance for the classification were the divergence of observed TTTGGG and TTCGGG singleton TVRs from the expected count, the number of breakpoints and the number of telomere insertions (Supplementary Table 3). It may be pivotal for further understanding of this mechanism to determine the causal relationship between these features and the ALT phenotype.

The scores resulting from the classifier can be interpreted as an ALT probability. As expected, ATRX/DAXX^{trunc} had a high ALT probability (mean = 0.91), while TERT^{mod} samples had a low ALT probability (mean = 0.13, Supplementary Fig. 16). A total of 17 samples without ATRX/DAXX^{trunc} mutations had an ALT probability of over 0.9, of which three had nontruncating ATRX/DAXX mutations and one sample had a frameshift insertion in ATRX and a TERT amplification (11 TERT copies, triploid). Across the entire dataset, most samples had a low ALT probability (Supplementary Fig. 17), suggesting that their TMM is telomerase based. This included some samples with ATRX/DAXX missense mutations, suggesting that the mutations in those samples may be more of a passenger event than functionally relevant. Tumor types with a high ALT probability were leiomyosarcoma, osteosarcoma, pancreatic endocrine tumors, and liposarcomas, in keeping with the known high prevalence of ALT in these entities^{37–39}.

Discussion

In this study, we have shown that the presence of ALT-associated mutations in tumors correlates with increased telomere content, enrichment of isolated TVRs in t-type context (singletons), a higher number of genomic breakpoints, and intrachromosomal telomere insertions (Fig. 5). In contrast, tumors with mutations associated with a possible telomerase activation showed moderate decrease of telomere content and increased TERT expression. Hence, TERT reactivation may not suffice to fully counteract the telomere loss associated with high proliferation and/or occur when advanced telomere attrition increases the selective pressure to activate telomere maintenance. The observed telomere content increase in ATRX/DAXX^{trunc} versus the decrease in TERT^{mod} samples is in agreement with the recent findings of Barthel et al.²⁶. The higher telomere content in ATRX/DAXX^{trunc} tumors indicates that the negative feedback loop that constrains telomere elongation to a physiological level in healthy telomerase-expressing cells^{40,41} is bypassed by the ALT process, while it seems to remain intact in telomerase-positive tumors. In addition to telomere

elongation, the increase of telomere content in ALT-positive tumors detected by sequencing-based methods may partly stem from aberrant intrachromosomal telomere insertions¹⁸ or extrachromosomal telomeric DNA⁴². Although almost all tumors must maintain their telomeres⁴³, we only detected somatic mutations highly associated with ALT or telomerase activation in a subset of the samples. In tumors arising from tissues with high rates of self-renewal, telomerase is likely to already be epigenetically activated in the cell of origin^{44,45}. Thus, telomere maintenance activating mutations occur more frequently in tumors derived from slowly replicating cells⁴⁶. In line with this assumption, we observed high rates of TMM-associated mutations in brain, liver, bladder, and kidney tumors and TERT expression despite lack of TMM-associated mutations in lymphomas, tumors of the gastrointestinal tract, and female reproductive system. The exceptions were pilocytic astrocytoma, pancreatic, and prostate adenocarcinoma, which all originate from slowly replicating tissues, but had almost no TMM-associated alterations. In pancreatic and prostate cancer, TERT activity has been detected^{47,48}, suggesting other means of telomerase activation. In pilocytic astrocytoma, neither telomerase expression/activity nor ALT was observed, but preALT characteristics have been reported^{49,50}. Therefore, a TMM may only be fully activated upon progression of this slow-growing tumor type. Medulloblastoma samples only had a TERT^{mod} frequency of 14% and one of the lowest average telomere contents in our study. While TERT^{mut} tend to occur in older patients of the SHH subgroup, the TERT promoter is frequently methylated in younger SHH patients and other medulloblastoma subgroups⁵¹. Interestingly, SHH medulloblastomas are thought to arise from granule neuron precursor cells⁵². This is a cell type with an extremely high rate of turnover during development and infancy, which may explain the TERT promoter methylation in younger SHH patients. In agreement with data suggesting that TERT expression is higher in TERT^{mut} than in TERT promoter methylated medulloblastomas⁵¹, we found that the telomere content was significantly higher in medulloblastomas with TERT^{mod} than in those without ($p = 0.0045$, Wilcoxon rank-sum test).

In our study, we systematically mapped telomere insertions into nontelomeric genomic regions using WGS data. They were most frequently accompanied by a loss of the adjacent chromosomal segment or located at copy-number neutral sites. Surprisingly, the latter telomere insertions were rarely two-sided and chromothripsis or other structural variations in the adjacent genomic regions occurred only in about half of the cases. As broken chromosome ends are highly unstable, the remaining segments must have undetected structural rearrangements, such as subclonal copy number changes or undetected DNA fusions. Taken together, the results suggest that we observe telomere healing or capture^{20,21} rather than telomere insertions followed by chromosomal instabilities^{18,53}. As microhomology around telomere insertion sites was frequent, the sequences were probably inserted by nonhomologous end-joining⁵⁴ or a microhomology-mediated mechanism⁵⁵.

Telomere insertions were particularly frequent in ATRX/DAXX^{trunc} tumors, in which the abundant extrachromosomal telomeric DNA expands the telomere template pool for microhomology-mediated double-strand repair. We speculate that in this cellular environment, a high load of genomic breakpoints subsequently leads to the observed disproportionately increased number of telomere capture-like events. Due to the stochastic nature of ALT, the likelihood of telomere crisis is elevated, an event that can induce BFB cycles^{56,57} and chromothripsis⁵⁸. Nevertheless, ALT can also stabilize telomeres, which has been shown to counteract genomic instability in certain instances⁵⁹. Either scenario may account for the higher prevalence of chromothripsis and BFB events in ATRX/DAXX^{trunc} cases observed in this study. Together with the correlation of




Fig. 5 Genomic footprints of telomerase-mediated telomere elongation and ALT. It is known that telomeres elongated by telomerase have a homologous length with few TVRs in distal telomeric regions (left), while ALT telomeres have heterogeneous lengths with an increased amount of TVRs (right). Moreover, ALT cells have abundant extrachromosomal telomeric sequences. From this study, we conclude that the chromosomes of ALT cells have a higher number of aberrant interstitial telomere insertions, most of which are one-sided and accompanied by a loss of the adjacent chromosomal segment. We also showed that several TVRs occurring as singletons are more abundant in ALT telomeres, while one singleton (TTTGGG) was more abundant in telomerase-elongated telomeres. Please note that it is currently undetermined whether the different types of singletons are located in proximal or distal telomeric regions.

telomere insertions and mutations in *TP53*, *RB1*, *MEN1*, *ATRX*, and *DAXX*, these findings suggest that genome instability and the ALT phenotype are prerequisites for a high number of telomere insertions. Mutations in *TP53*, *RB1*, and *MEN1* have been associated with impaired DNA damage response and repair^{60–62}. This may make telomere crisis and genomic rearrangements more likely, while at the same time preventing apoptosis or senescence. Supporting all of these associations, an increased incidence of ALT in combination with chromothripsis was observed in SHH medulloblastomas with *TP53* germline or somatic mutations⁵⁹.

Telomere elongation by ALT or telomerase enriches distinct TVRs¹⁵. Here, we report a stronger association of singleton TVRs with *ATRX/DAXX*^{trunc} mutations than TVRs in an arbitrary context. The increase of TVRs has been attributed to the inclusion of subtelomeric regions during ALT via homologous recombination¹⁴. Whether telomeric sequences with lower TVR density are under positive selection or regions with higher TVR density are under negative selection remains to be clarified.

A possible function for TVRs has been reported in ALT-positive cell lines, where TCAGGG repeats that recruit nuclear receptors were enriched^{14,18}. This enrichment was confirmed in a subset of primary *ATRX/DAXX*^{trunc} tumor samples in our study. However, we found a more pronounced enrichment of TTCGGG or TGAGGG. While TGAGGG has previously been associated with ALT¹⁴, the high prevalence of TTCGGG singletons in ALT is a novel discovery. No proteins with strong affinity to these two TVRs are currently known. This may indicate a more passive mode of action, for instance deprotection of telomeres by shelterin displacement¹⁴, and/or alteration of the telomeric G-quadruplex conformation¹⁵. Notably, we report for the first time that TTTGGG singletons but not TTTGGG in arbitrary context were depleted in *ATRX/DAXX*^{trunc} samples. This finding underlines the necessity to consider the sequence context of

TVRs. None of the current models of ALT provide an explanation for this specific TVR depletion.

The methodologies presented here expand the established telomere content estimation from genomic sequencing by the context-dependent analysis of TVRs and telomere insertions. By applying them within a large-scale pan-cancer study, we provide a valuable resource for the further characterization of different TMMs in cancer cells based on WGS data.

Methods

Sequencing data. WGS and expression data were obtained from the ICGC/TCGA PCAWG project²³. The WGS reads of tumor and control samples were aligned with bwa-mem by the PCAWG-tech group. Control samples were usually blood. In a small number of cases, the controls were obtained from tumor-adjacent or other tissue²³. Tumors with multiple samples were excluded from this study, as well as one sample pair with reads shorter than 30 bp. Expression data was in the format of normalized RNA read counts per gene and only available for 1033 of 2519 patients. RNA sequencing BAM files aligned with STAR by the PCAWG-tech group were available for 867 tumor samples. To avoid confusion, we used the name “(central nervous system) CNS-LGG” (lower grade glioma, i.e., grades II and III) for the “CNS-Oligo” tumor type, because several samples in this cohort did not have the genetic markers (i.e., 1p/19q co-deletions) for oligodendroglioma required by the WHO⁶³. A detailed overview of tumor type abbreviations with the included subtypes is given in Supplementary Table 4.

Mutation data. Somatic simple nucleotide, structural variations, and copy numbers were obtained from the PCAWG consensus calls (Synapse IDs syn7364923, syn7596712, and syn8042992, respectively). Structural variations were not available for 24 tumor samples.

Telomere read extraction and computational telomere content estimation.

The telomere content of WGS samples was determined using the software tool TelomereHunter⁶⁴. In short, telomeric reads containing six nonconsecutive instances of the four most common telomeric repeat types (TTAGGG, TCAGGG, TGAGGG, and TTGGGG) were extracted. For the further analysis, only unmapped reads or reads with a very low alignment confidence (mapping quality lower than 8) were considered. The telomere content was determined by normalizing the telomere read count by all reads in the sample with a GC content of 48–52%.

Determining TMM-associated mutations. Samples with a truncating *ATRX* or *DAXX* alteration (frame-shift insertion/deletion, stop-codon gain, or structural variation breakpoint within the gene) were defined as *ATRX/DAXX*^{trunc}, samples with other simple nucleotide variants were defined as *ATRX/DAXX*^{non-trunc}. Deletions that only affected intronic regions of *ATRX* were not considered. Of note, a frame-shift deletion called in the tumor sample of donor SP112201 was excluded as a false positive after visual inspection in the Integrative Genomics Viewer (IGV)^{65,66}. Samples with a structural variation breakpoint on the plus strand 20 kb upstream of *TERT* the TSS were defined as *TERT*^{SV}. *TERT*^{amp} samples had at least six additional copies of the *TERT* gene compared to the mean ploidy of the sample. Tumor samples with a C228T or C250T *TERT* promoter mutation were defined as *TERT*^{mut}. Due to the low sequencing coverage at the *TERT* promoter, these mutations were called using less stringent criteria (at least two reads with the mutated base, mutational frequency of at least 20%) in addition to the PCAWG consensus single nucleotide variant (SNV) calls (Synapse ID syn7364923). If multiple of these *TERT* modifications were present, the sample was defined as *TERT*^{mult}. Samples with these *TERT* alterations were summarized as *TERT*^{mod}. Samples without any of these alterations were defined as “wild type”. If a sample had both a *TERT*^{mod} alteration and an *ATRX/DAXX* alteration, it was defined as “mixed”. For some analyses, *ATRX/DAXX*^{non-trunc}, mixed and wild-type samples were summarized as “other”.

Overlap of juxtaposed positions upstream of *TERT* and predicted super-enhancers. For the closest structural variation (SV) of each tumor sample to the *TERT* TSS, the juxtaposed genomic coordinates were compared to 65,950 predicted super-enhancers from the dbSUPER database³⁰. Only SVs on the plus strand and within 1 mb of the *TERT* TSS were considered. Overlaps of juxtaposed positions with super-enhancer sites were defined as direct overlaps. Super-enhancer sites within 1 mb of the juxtaposed position were defined as indirect overlaps.

Telomere insertion detection. To find insertions of telomeric sequences into nontelomeric regions in the genome, we searched for tumor-specific discordant paired-end reads, where one end was an extracted telomere read and the other end was nontelomeric and uniquely mapped to a chromosome (mapping quality > 30). In 1 kb regions containing at least three discordant reads in the tumor sample and none in the matching control, exact positions of telomere insertions were defined by at least three split reads spanning the insertion site. The split reads had to contain at least one TTAGGG repeat. Regions with discordant read pairs in at least 15 control samples were excluded. Finally, the insertion sites were visualized using IGV^{65,66} to identify and remove remaining false positives. A telomere insertion was defined as two-sided if another telomere insertion in opposite orientation was found in the downstream 10 kb of the reference genome with the same repeat on the forward strand. Otherwise it was defined as one-sided.

Breakpoint detection. Breakpoints were obtained from the consensus breakpoint list of structural and copy number variation calls (Synapse ID syn8042992). In short, six copy number detection tools were run on all samples, including the consensus structural variations breakpoints. From the obtained chromosomal segments of the individual callers another set of consensus breakpoints was calculated.

Chromothripsis detection. To identify chromothripsis events, we extended the set of statistical criteria proposed by Korbel and Campbell⁶⁷. The basic idea is to determine whether there is a statistically significant number of interleaved structural variants in a contiguous genomic region. We did this by constructing a graph whose nodes correspond to SVs and whose edges connect interleaved SVs. The identified clusters of SVs were also tested for the presence of alternating copy number and loss-of-heterozygosity patterns. The resulting chromothripsis calls were validated visually. The full description of the methodology and the detailed patterns of chromothripsis events in the genomes are described in a separate study²⁴. Only high-confidence chromothripsis calls were included in this analysis.

BFB detection. At least two fold-back inversions on the same chromosome arm were defined as BFB events. Fold-back inversions had to fulfill the following requirements adapted from Cheng et al.⁶⁸: (1) the two breakpoints of the inversion are less than 20 kb apart; (2) the inversion does not have a reciprocal partner, such that $\text{inversion1_start} < \text{inversion2_start} < \text{inversion1_end} < \text{inversion2_end}$; and (3) there is a copy number change at the inversion site.

Copy number changes at telomere insertion sites. Copy numbers of chromosomal segments were obtained from the PCAWG consensus calls (Synapse ID syn8042992). Copy numbers reveal gains or losses of chromosomal segments based on coverage and B-allele frequency, but were here limited to segments of at least 10 kb. The breakpoint estimations could differ from the actual site by up to 50 kb. Therefore, telomere insertions were assigned to the closest breakpoint within 50 kb. If there was no breakpoint within 50 kb or the copy numbers at either side of the telomere insertion were the same, the copy number change at the telomere insertion was defined as neutral.

Structural variations near telomere insertion sites. Structural variation annotation was obtained from the PCAWG consensus calls (Synapse ID syn7596712), which was based on discordant mate pairs and split reads, providing exact breakpoints. Because copy number variations smaller than 10 kb were not detected by copy number callers, small deletions next to the telomere insertion site may be missed. We therefore searched for structural variations within 10 kb of a telomere insertion to detect these cases.

Candidate gene selection for correlation analysis. A list of 1725 telomere maintenance associated human genes was obtained from TelNet³³ on February 20, 2017. After removing genes without a unique Ensembl IDs in the GENCODE⁶⁹ v19 HAVANA annotation, the remaining 1686 genes were used for correlation of telomere insertions and simple nucleotide variants.

TERRA detection. TelomereHunter was run on RNA-Seq BAM files to count reads containing at least *k* nonconsecutive instances of the four most common telomeric repeat types (TTAGGG, TCAGGG, TGAGGG, and TTGGGG). The repeat threshold *k* was chosen depending on the read length: *k* = 7 for 45–50 bp, *k* = 10 for 75–76 bp, and *k* = 14 for 99–101 bp. The resulting TERRA read counts were normalized by the total number of reads in the sample. For better readability, this number was multiplied by 1 Mio.

Detection of TVRs. TVRs were detected by searching for hexamers of the type NNNGGG in the extracted telomere reads. Each base was required to have a base quality of at least 20. The neighboring 18 bp on either side of the TVR were determined. For further analysis, NNNGGG TVRs were once computed for arbitrary context and once for t-type context ((TTAGGG)₃-NNNGGG-(TTAGGG)₃, also called “singletons”). The absolute counts were normalized to the total number of reads in the sample. The expected pattern counts in arbitrary context were calculated as: telomere content tumor/control log2 ratio. The expected singleton counts at different telomere content tumor/control log2 ratios were taken from the regression line through *TERT*^{mod} samples. The singleton occurrence heatmap was generated using the R package ComplexHeatmap⁷⁰.

Classifier for predicting active TMMs. A random forest classifier to distinguish *ATRX/DAXX*^{trunc} and *TERT*^{mod} samples was built using the R packages “randomForest”⁷¹ and “caret”⁷² with the following eight features: telomere content tumor/control log2 ratio, number of telomere insertions, number of breakpoints, and the distance of TTAGGG, TCAGGG, TTGGGG, TCCGGG, and TTTGGG singletons (i.e., repeats in a t-type context) to their expected occurrence. To deal with the imbalance in the data set (i.e., 266 *TERT*^{mod} samples versus 63 *ATRX/DAXX*^{trunc} samples without missing data), the model was trained with a down-sampled training set. The performance was determined using 10-fold cross-validation.

Statistics. Differences between *ATRX/DAXX*^{trunc} and *TERT*^{mod} samples in terms of telomere content, percent breakpoints with telomere insertions, and singleton repeat abundance were tested using two-sided Wilcoxon rank-sum tests. Singleton repeat abundance *p*-values were corrected for multiple testing using the Bonferroni method. To reduce the influence of outliers, correlation coefficients were calculated with the Spearman method. Correlation between control telomere content and age as well as tumor and control telomere content was tested with linear regression. All statistical analyses were carried out using R (R Foundation for Statistical Computing).

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Somatic and germline variant calls, mutational signatures, subclonal reconstructions, transcript abundance, splice calls, and other core data generated by the ICGC/TCGA PCAWG Consortium is described here²³ and available for download at [<https://dcc.icgc.org/releases/PCAWG>]. Additional information on accessing the data, including raw read files, can be found at [<https://docs.icgc.org/pawg/data/>]. In accordance with the data access policies of the ICGC and TCGA projects, most molecular, clinical and specimen data are in an open tier which does not require access approval. To access potentially identification information, such as germline alleles and underlying sequencing data, researchers will need to apply to the TCGA Data Access Committee (DAC) via dbGaP for access to the TCGA portion of the dataset, and to the ICGC Data Access Compliance Office (DACO) for the ICGC portion. In addition, to access somatic SNVs derived from TCGA donors, researchers will also need to obtain dbGaP authorization.

Derived data sets described specifically used in this manuscript are catalogued on Synapse. Data access is possible via the ICGC data portal (DCC), where the original files are split into ICGC and TCGA subsets due to different access regulations:

somatic simple nucleotide calls (syn7364923): and [https://dcc.icgc.org/releases/PCAWG/consensus_snv_indel],
structural variation calls (syn7596712): and [https://dcc.icgc.org/releases/PCAWG/consensus_sv],

copy number calls (syn8042992); and [https://dcc.icgc.org/releases/PCAWG/consensus_cnv].

Code availability

The software TelomereHunter used for the in silico analysis of the genomic footprints of activated TMMs is available from [<https://www.dkfz.de/en/applied-bioinformatics/telomerehunter/telomerehunter.html>]. The core computational pipelines used by the PCAWG Consortium for alignment, quality control, and variant calling are available to the public at <https://dockstore.org/search?search=pcawg> under the GNU General Public License v3.0, which allows for reuse and distribution.

Received: 22 November 2017; Accepted: 26 November 2019;

Published online: 05 February 2020

References

- O'Sullivan, R. J. & Karlseder, J. Telomeres: protecting chromosomes against genome instability. *Nat. Rev. Mol. Cell Biol.* **11**, 171–181 (2010).
- Allshire, R. C., Dempster, M. & Hastie, N. D. Human telomeres contain at least three types of G-rich repeat distributed non-randomly. *Nucleic Acids Res.* **17**, 4611–4627 (1989).
- Baird, D. M., Jeffreys, A. J. & Royle, N. J. Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere. *EMBO J.* **14**, 5433–5443 (1995).
- Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. *Nature* **345**, 458–460 (1990).
- d'Adda di Fagnana, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. *Nature* **426**, 194–198 (2003).
- Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W. & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. *Dev. Genet.* **18**, 173–179 (1996).
- Zhang, A. et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. *Cancer Res.* **60**, 6230–6235 (2000).
- Peifer, M. et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. *Nature* **526**, 700–704 (2015).
- Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. *Science* **339**, 959–961 (2013).
- Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. *Science* **339**, 957–959 (2013).
- Cesare, A. J. & Reddel, R. R. Alternative lengthening of telomeres: models, mechanisms and implications. *Nat. Rev. Genet.* **11**, 319–330 (2010).
- Heaphy, C. M. et al. Altered telomeres in tumors with ATRX and DAXX mutations. *Science* **333**, 425 (2011).
- Varley, H., Pickett, H. A., Foxon, J. L., Reddel, R. R. & Royle, N. J. Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. *Nat. Genet.* **30**, 301–305 (2002).
- Conomos, D. et al. Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. *J. Cell Biol.* **199**, 893–906 (2012).
- Lee, M. et al. Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. *Nucleic Acids Res.* **42**, 1733–1746 (2014).
- Lovejoy, C. A. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. *PLoS Genet.* **8**, e1002772 (2012).
- Lin, K. W. & Yan, J. Endings in the middle: current knowledge of interstitial telomeric sequences. *Mutat. Res.* **658**, 95–110 (2008).
- Marzec, P. et al. Nuclear-receptor-mediated telomere insertion leads to genome instability in ALT cancers. *Cell* **160**, 913–927 (2015).
- Wilkie, A. O., Lamb, J., Harris, P. C., Finney, R. D. & Higgs, D. R. A truncated human chromosome 16 associated with alpha thalassaemia is stabilized by addition of telomeric repeat (TTAGGG)_n. *Nature* **346**, 868–871 (1990).
- Flint, J. et al. Healing of broken human chromosomes by the addition of telomeric repeats. *Am. J. Hum. Genet.* **55**, 505–512 (1994).
- Meltzer, P. S., Guan, X. Y. & Trent, J. M. Telomere capture stabilizes chromosome breakage. *Nat. Genet.* **4**, 252–255 (1993).
- Sljepcevic, P. & Bryant, P. E. Chromosome healing, telomere capture and mechanisms of radiation-induced chromosome breakage. *Int. J. Radiat. Biol.* **73**, 1–13 (1998).
- The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature* <https://doi.org/10.1038/s41586-020-1969-6> (2020).
- Cortes-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nat. Genet.* <https://doi.org/10.1038/s41588-019-0576-7> (2020).
- Lee, M. et al. Comparative analysis of whole genome sequencing-based telomere length measurement techniques. *Methods* **114**, 4–15 (2017).
- Barthel, F. P. et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. *Nat. Genet.* **49**, 349–357 (2017).
- Slagboom, P. E., Droog, S. & Boomsma, D. I. Genetic determination of telomere size in humans: a twin study of three age groups. *Am. J. Hum. Genet.* **55**, 876–882 (1994).
- Codd, V. et al. Identification of seven loci affecting mean telomere length and their association with disease. *Nat. Genet.* **45**, 422–427, 427e1–2 (2013).
- Shammas, M. A. Telomeres, lifestyle, cancer, and aging. *Curr. Opin. Clin. Nutr. Metab. Care* **14**, 28–34 (2011).
- Khan, A. & Zhang, X. dbSUPER: a database of super-enhancers in mouse and human genome. *Nucleic Acids Res.* **44**, D164–D171 (2016).
- Heaphy, C. M. et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. *Am. J. Pathol.* **179**, 1608–1615 (2011).
- Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* **144**, 27–40 (2011).
- Braun, D. M., Chung, I., Keppler, N., Deeg, K. I. & Rippe, K. TelNet - a database for human and yeast genes involved in telomere maintenance. *BMC Genet.* **19**, 32 (2018).
- Hu, Y. et al. Telomerase-null survivor screening identifies novel telomere recombination regulators. *PLoS Genet.* **9**, e1003208 (2013).
- Askree, S. H. et al. A genome-wide screen for *Saccharomyces cerevisiae* deletion mutants that affect telomere length. *Proc. Natl Acad. Sci. USA* **101**, 8658–8663 (2004).
- Patil, M., Pabla, N. & Dong, Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. *Cell Mol. Life Sci.* **70**, 4009–4021 (2013).
- Amorim, J. P., Santos, G., Vinagre, J. & Soares, P. The role of ATRX in the alternative lengthening of telomeres (ALT) phenotype. *Genes (Basel)* **7**, 66 (2016).
- de Wilde, R. F. et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. *Mod. Pathol.* **25**, 1033–1039 (2012).
- Chudasama, P. et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. *Nat. Commun.* **9**, 144 (2018).
- van Steensel, B. & de Lange, T. Control of telomere length by the human telomeric protein TRF1. *Nature* **385**, 740–743 (1997).
- Hockemeyer, D. & Collins, K. Control of telomerase action at human telomeres. *Nat. Struct. Mol. Biol.* **22**, 848–852 (2015).
- Nabetani, A. & Ishikawa, F. Unusual telomeric DNAs in human telomerase-negative immortalized cells. *Mol. Cell Biol.* **29**, 703–713 (2009).
- Reddel, R. R. Telomere maintenance mechanisms in cancer: clinical implications. *Curr. Pharm. Des.* **20**, 6361–6374 (2014).
- Guilleret, I. et al. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. *Int. J. Cancer* **101**, 335–341 (2002).
- Takasawa, K. et al. DNA hypermethylation enhanced telomerase reverse transcriptase expression in human-induced pluripotent stem cells. *Hum. Cell* **31**, 78–86 (2018).
- Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc. Natl Acad. Sci. USA* **110**, 6021–6026 (2013).
- Hiyama, E. et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. *Cancer Res.* **57**, 326–331 (1997).
- Sommerfeld, H. J. et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. *Cancer Res.* **56**, 218–222 (1996).
- Chong, E. Y., Lam, P. Y., Poon, W. S. & Ng, H. K. Telomerase expression in gliomas including the nonastrocytic tumors. *Hum. Pathol.* **29**, 599–603 (1998).
- Slatter, T. et al. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. *Am. J. Pathol.* **177**, 2694–2700 (2010).
- Lindsey, J. C. et al. TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. *Acta Neuropathol.* **127**, 307–309 (2014).
- Schuller, U. et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. *Cancer Cell* **14**, 123–134 (2008).
- Jia, P., Chastain, M., Zou, Y., Her, C. & Chai, W. Human MLH1 suppresses the insertion of telomeric sequences at intra-chromosomal sites in telomerase-expressing cells. *Nucleic Acids Res.* **45**, 1219–1232 (2016).
- Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu. Rev. Biochem.* **79**, 181–211 (2010).
- Ottaviani, D., LeCain, M. & Sheer, D. The role of microhomology in genomic structural variation. *Trends Genet.* **30**, 85–94 (2014).
- McClintock, B. The stability of broken ends of chromosomes in *Zea mays*. *Genetics* **26**, 234–282 (1941).

57. Lo, A. W. et al. DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. *Neoplasia* **4**, 531–538 (2002).
58. Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J. & de Lange, T. Chromothripsis and kataegis induced by telomere crisis. *Cell* **163**, 1641–1654 (2015).
59. Ernst, A. et al. Telomere dysfunction and chromothripsis. *Int. J. Cancer* **138**, 2905–2914 (2016).
60. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. *Nature* **408**, 307–310 (2000).
61. Huang, P. H., Cook, R. & Mittnacht, S. RB in DNA repair. *Oncotarget* **6**, 20746–20747 (2015).
62. Gallo, A., Agnese, S., Esposito, I., Galgani, M. & Avvedimento, V. E. Menin stimulates homology-directed DNA repair. *FEBS Lett.* **584**, 4531–4536 (2010).
63. Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* **131**, 803–820 (2016).
64. Feuerbach, L. et al. TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. *BMC Bioinforma.* **20**, 272 (2019).
65. Robinson, J. T. et al. Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
66. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief. Bioinform.* **14**, 178–192 (2013).
67. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. *Cell* **152**, 1226–1236 (2013).
68. Cheng, C. et al. Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. *Am. J. Hum. Genet.* **98**, 256–274 (2016).
69. Harrow, J. et al. GENCODE: the reference human genome annotation for The ENCODE Project. *Genome Res.* **22**, 1760–1774 (2012).
70. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849 (2016).
71. Liaw, A. W. M. Classification and regression by randomForest. *R. News* **2**, 18–22 (2002).
72. Kuhn, M. Building Predictive Models in R Using the caret Package. *J. Stat. Softw.* **28** (2008).

Acknowledgements

We thank J. Kerssemakers, M. Prinz, and M. Heinold for their help in data processing. We thank I. Buchhalter for annotation of simple nucleotide variations. We thank D. Hübschmann for his support in correlation analysis. We thank all TelNet curators for sharing the results of their extensive literature research. We thank K.I. Deeg, P. Lichter, and S.M. Pfister for their support in early stages of the study. We thank I. Chung for comments and discussion. The work was supported by grants from the German Federal Ministry of Education and Research (BMBF) within the eMed program (project CancerTelSys, 01ZX1302 to K.R.) and the program for medical genome research (01KU1001A, -B, -C, and -D; 01KU1505A). S.D.K. received funding from the German Research Foundation (DFG) in research priority program SPP1463 (grant no. Br3535/1-2). I.C.C. has received funding from the European Union's Framework Programme For Research and Innovation Horizon 2020 (2014–2020) under the Marie Skłodowska-Curie Grant Agreement No. 703543. We acknowledge the contributions of the many clinical networks across ICGC and TCGA who provided samples and data to the PCAWG

Consortium, and the contributions of the Technical Working Group and the Germline Working Group of the PCAWG Consortium for collation, realignment, and harmonised variant calling of the cancer genomes used in this study. We thank the patients and their families for their participation in the individual ICGC and TCGA projects.

Author contributions

L.S. was involved in all bioinformatical analyses. C.H. performed structural variation annotation, principal component analysis and classification. L.F. was responsible for correlation analysis. S.D.K. analyzed gene expression data and was involved in visualization. L.S., P.G. and L.F. were involved in method development. K.K. and M.S. were involved in copy number analysis. R.K. was involved in data preprocessing. D.M.B. developed and curated the TelNet database. I.C.C., R.X. and P.J.P. provided regions of chromothripsis. B.H. was involved in early stages of experimental design. R.E. was responsible for data management and creating the IT-infrastructure. K.R. and D.T.W.J. provided insights into telomere biology. D.T.W.J. and L.F. conceived the study. B.B. and L.F. oversaw the experimental design and execution. L.S. and L.F. wrote the manuscript with contributions by K.K., D.M.B., M.S., K.R. and D.T.W.J. The PCAWG-Structural Variation Working Group provided valuable advice and feedback. Rameen Beroukhi and Peter J. Campbell were working group or project co-leaders, respectively.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41467-019-13824-9>.

Correspondence and requests for materials should be addressed to L.F.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

PCAWG-Structural Variation Working Group

Kadir C. Akdemir¹⁴, Eva G. Alvarez^{15,16,17}, Adrian Baez-Ortega¹⁸, Rameen Beroukhi^{19,20,21}, Paul C. Boutros^{22,23,24,25}, David D.L. Bowtell^{26,27}, Benedikt Brors^{1,28,29}, Kathleen H. Burns³⁰, Peter J. Campbell^{31,32}, Kin Chan³³, Ken Chen¹⁴, Isidro Cortés-Ciriano^{6,7,34}, Ana Dueso-Barroso³⁵, Andrew J. Dunford¹⁹, Paul A. Edwards^{36,37}, Xavier Estivill^{38,39}, Dariush Etemadmoghadam^{26,27}, Lars Feuerbach¹, J. Lynn Fink^{35,40}, Milana Frenkel-Morgenstern⁴¹, Dale W. Garsed^{26,27}, Mark Gerstein^{42,43,44}, Dmitry A. Gordenin⁴⁵, David Haan⁴⁶, James E. Haber⁴⁷, Julian M. Hess^{19,48}, Barbara Hutter^{11,29,49}, Marcin Imielinski^{50,51}, David T.W. Jones^{52,53}, Young Seok Ju^{1,31,54}, Marat D. Kazanov^{55,56,57}, Leszek J. Klimczak⁵⁸, Youngil Koh^{59,60}, Jan O. Korbel^{61,62}, Kiran Kumar¹⁹, Eunjung Alice Lee⁶³,

Jake June-Koo Lee^{6,8}, Yilong Li³¹, Andy G. Lynch^{36,37,64}, Geoff Macintyre³⁶, Florian Markowitz^{36,37}, Iñigo Martincorena³¹, Alexander Martinez-Fundichely^{65,66,67}, Matthew Meyerson^{19,21,68,69,70}, Satoru Miyano⁷¹, Hidewaki Nakagawa⁷², Fabio C.P. Navarro⁴³, Stephan Ossowski^{39,73,74}, Peter J. Park^{6,8}, John V. Pearson^{75,76}, Montserrat Puiggròs³⁵, Karsten Rippe⁷⁷, Nicola D. Roberts³¹, Steven A. Roberts⁷⁸, Bernardo Rodriguez-Martin^{15,16,17}, Steven E. Schumacher^{19,79}, Ralph Scully⁸⁰, Mark Shackleton^{27,81}, Nikos Sidiropoulos⁸², Lina Sieverling^{1,2}, Chip Stewart¹⁹, David Torrents^{35,83}, Jose M.C. Tubio^{15,16,17}, Izar Villasante³⁵, Nicola Waddell^{75,76}, Jeremiah A. Wala^{6,19,21,68}, Joachim Weischenfeldt^{62,82,84}, Lixing Yang⁸⁵, Xiaotong Yao^{50,86}, Sung-Soo Yoon⁶⁰, Jorge Zamora^{15,16,17,31} & Cheng-Zhong Zhang^{19,21,68}

¹⁴University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ¹⁵Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Santiago de Compostela 15706, Spain. ¹⁶Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15706, Spain. ¹⁷The Biomedical Research Centre (CINBIO), Universidade de Vigo, Vigo 36310, Spain. ¹⁸Transmissible Cancer Group, Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK. ¹⁹Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. ²⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. ²¹Harvard Medical School, Boston, MA 02115, USA. ²²Computational Biology Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada. ²³Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1A8, Canada. ²⁴Department of Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada. ²⁵University of California Los Angeles, Los Angeles, CA 90095, USA. ²⁶Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. ²⁷Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia. ²⁸German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. ²⁹National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg 69120, Germany. ³⁰Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. ³¹Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK. ³²Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK. ³³University of Ottawa Faculty of Medicine, Department of Biochemistry, Microbiology and Immunology, Ottawa, ON K1H 8M5, Canada. ³⁴Ludwig Center, Harvard Medical School, Boston, MA 02115, USA. ³⁵Barcelona Supercomputing Center (BSC), Barcelona 08034, Spain. ³⁶Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. ³⁷University of Cambridge, Cambridge CB2 1TN, UK. ³⁸Quantitative Genomics Laboratories (qGenomics), Barcelona 08950, Spain. ³⁹Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona 08003, Spain. ⁴⁰Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia. ⁴¹The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 13195, Israel. ⁴²Department of Computer Science, Yale University, New Haven, CT 06520, USA. ⁴³Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA. ⁴⁴Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA. ⁴⁵Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), Durham, NC 27709, USA. ⁴⁶Biomolecular Engineering Department, University of California, Santa Cruz, Santa Cruz, CA 95064, USA. ⁴⁷Brandeis University, Waltham, MA 02254, USA. ⁴⁸Massachusetts General Hospital Center for Cancer Research, Charlestown, MA 02129, USA. ⁴⁹Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. ⁵⁰New York Genome Center, New York, NY 10013, USA. ⁵¹Weill Cornell Medicine, New York, NY 10065, USA. ⁵²Hopp Children's Cancer Center (KiTZ), Heidelberg 69120, Germany. ⁵³Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. ⁵⁴Korea Advanced Institute of Science and Technology, Daejeon 34141, South Korea. ⁵⁵Skolkovo Institute of Science and Technology, Moscow 121205, Russia. ⁵⁶A.A.Kharkevich Institute of Information Transmission Problems, Moscow 127051, Russia. ⁵⁷Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117997, Russia. ⁵⁸Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences (NIEHS), Durham, NC 27709, USA. ⁵⁹Center For Medical Innovation, Seoul National University Hospital, Seoul 03080, South Korea. ⁶⁰Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, South Korea. ⁶¹European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK. ⁶²Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg 69117, Germany. ⁶³Division of Genetics and Genomics, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA. ⁶⁴School of Medicine/School of Mathematics and Statistics, University of St Andrews, St Andrews, Fife KY16 9SS, UK. ⁶⁵Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA. ⁶⁶Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10065, USA. ⁶⁷Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA. ⁶⁸Dana-Farber Cancer Institute, Boston, MA 02215, USA. ⁶⁹Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern 3010, Switzerland. ⁷⁰Department of Pathology, The University of Melbourne, Melbourne, VIC 3052, Australia. ⁷¹The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ⁷²RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. ⁷³Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72074, Germany. ⁷⁴Universitat Pompeu Fabra (UPF), Barcelona 08003, Spain. ⁷⁵Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia. ⁷⁶Institute for Molecular Bioscience, University of Queensland, St Lucia, Brisbane, QLD 4072, Australia. ⁷⁷German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. ⁷⁸School of Molecular Biosciences and Center for Reproductive Biology, Washington State University, Pullman, WA 99164, USA. ⁷⁹Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. ⁸⁰Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. ⁸¹Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC 3000, Australia. ⁸²Finsen Laboratory and Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen 2200, Denmark. ⁸³Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain. ⁸⁴Department of Urology, Charité Universitätsmedizin Berlin, Berlin 10117, Germany. ⁸⁵Ben May Department for Cancer Research, Department of Human Genetics, The University of Chicago, Chicago, IL 60637, USA. ⁸⁶Tri-institutional PhD program of computational biology and medicine, Weill Cornell Medicine, New York, NY 10065, USA